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Both gastric and intestinal phenotypic markers are known to be expressed in gastric carcinomas, irrespective of their histologic type.
In the present study, the relation between gastric and intestinal phenotypic marker expression in gastric carcinomas and the
recurrence pattern after surgery was examined. The phenotypic marker expression of the tumour was determined by examining the
expression of human gastric mucin (HGM), MUC6, MUC2 and CD10 in 213 advanced gastric carcinomas in 213 patients who had
undergone a curative resection (97 died from recurrent gastric carcinoma and 116 were alive without recurrence at the end of the
follow-up period). Tumours were classified into gastric (G), gastric and intestinal mixed (GI), intestinal (I) or unclassified (UC)
phenotypes according to the immunopositivity of HGM, MUC6, MUC2 and CD10 stainings. The incidence of HGM-positive tumours
and MUC2-negative tumours was significantly higher in tumours with peritoneal recurrence than in tumours without recurrence
(73.3%, 44 out of 60 cases vs 54.3%, 63 out of 116 (P¼0.022); and 70.0%, 42 out of 60 vs 38.8%, 45 out of 116 (P¼0.0002),
respectively). The incidence of G-phenotype tumours was also significantly higher in tumours with peritoneal recurrence than in
tumours without recurrence (58.3%, 35 out of 60 cases vs 28.4%, 33 out of 116 (P¼0.0002)). The incidence of MUC2-negative
tumours and CD10-positive tumours was significantly higher in tumours with haematogenous recurrence than in tumours without
recurrence (62.5%, 20 out of 32 cases vs 38.8%, 45 out of 116 (P¼0.028); and 43.8%, 14 out of 32 vs 23.3%, 27 out of 116
(P¼0.039); respectively). Our present findings show that the gastric and intestinal phenotypic marker expression of the tumour,
determined by immunohistochemical staining for HGM, MUC6, MUC2 and CD10, can be used to predict the pattern of gastric
carcinoma recurrence after curative resection.
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Gastric carcinoma is histologically classified in two manners,
differentiated vs undifferentiated, or intestinal vs diffuse, based on
the tendency of gland formation (Lauren, 1965; Nakamura et al,
1968). However, recent mucin histochemical and immunohisto-
chemical examinations have demonstrated that gastric and
intestinal phenotypic cell markers are widely expressed in gastric
carcinomas, irrespective of their histologic type (Tatematsu et al,
1990; Egashira et al, 1999; Endoh et al, 1999, 2000; Koseki
et al, 2000; Saito et al, 2001; Tajima et al, 2001a,b, 2003; Tsukashita
et al, 2001; Kabashima et al, 2002; Shibata et al, 2003). Several
authors have reported that gastric carcinomas can be classified as
having either a gastric (G), gastric and intestinal mixed (GI) or
intestinal (I) phenotype, depending on the immunopositivity of
human gastric mucin (HGM), MUC6, MUC2 and CD10 stainings
(Tajima et al, 2001b, 2003; Kabashima et al, 2002). Human gastric
mucin, MUC6, MUC2 and CD10 specifically express in gastric
surface mucous cells, pyloric gland cells, intestinal goblet cells
of the mature gastrointestinal tract and brush border of intestinal
epithelial cells, respectively. We previously reported that
G-phenotype tumours accounted for 27.7% of differentiated
tumours, often referred to as intestinal-type tumours according
to Lauren (1965), while I-phenotype tumours accounted for 10.1%
of undifferentiated tumours (Tajima et al, 2001b). The phenotypic
marker expression of tumours is conventionally thought to imitate
that of the tissue of origin. Thus, the previous data described above
suggest that gastric carcinomas can occur in various types of
gastric mucosa, although differentiated tumours have generally
been considered to arise from gastric mucosa with intestinal
metaplasia and undifferentiated tumours to arise from ordinary
gastric mucosa without intestinal metaplasia (Lauren, 1965;
Nakamura et al, 1968). Recently, G-phenotype tumours have been
associated with poorer outcome and greater malignant potential in
the incipient phase of invasion and metastasis, compared with
those of other phenotype tumours (Endoh et al, 1999; Koseki et al,
2000; Saito et al, 2001; Tajima et al, 2001b; Kabashima et al, 2002;
Shibata et al, 2003). Therefore, phenotypic classification could be
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yuseful not only for investigating the tumorigenesis of gastric
carcinoma, but also for evaluating tumour aggressiveness.
Phenotypic expression in gastric carcinomas has also been
reported to be strongly dependent on genetic changes (Endoh
et al, 2000).
Early tumour detection, standardised surgical treatment with
systematic lymph node dissection and appropriate chemotherapy
have improved the survival of patients with gastric carcinoma
(Otsuji et al, 1998). However, recurrences are likely to assume a
variety of forms in various different organs, even after a curative
resection of the gastric carcinoma. Risk factors for peritoneal
recurrence have been reported to include an undifferentiated
histological type, infiltrative tumour growth and serosal invasion,
while risk factors for haematogenous recurrence have been
reported to include a vessel invasion, differentiated histological
type and expansive tumour growth (Maehara et al, 1996; Yoo et al,
2000; Ohno et al, 2003; Roviello et al, 2003). The prediction of
recurrence patterns after surgery could help better follow-up
programmes and appropriate treatment strategies to be designed
for gastric carcinoma patients. However, the relation between
gastric and intestinal phenotypic marker expression in gastric
carcinomas and the recurrence pattern after surgery has not been
investigated.
In the present study, we examined surgically resected tumour
specimens from 213 patients with advanced gastric carcinoma
using HGM, MUC6, MUC2 and CD10 immunohistochemical
stainings to clarify the relation between gastric and intestinal
phenotypic marker expression in gastric carcinomas and the
recurrence pattern after surgery.
MATERIALS AND METHODS
Patients
Our series consisted of 213 patients who had undergone potentially
curative resections for advanced gastric carcinoma between 1994
and 1998 at the Showa University Hospital and the Toyosu
Hospital, Showa University, Tokyo, Japan. A total gastrectomy, or
a distal or proximal subtotal gastrectomy with lymph node
dissection, was performed, depending on the tumour location
and surgical margin. Each patient underwent D2 (141 cases) or D3
(72 cases) lymphadenectomy and a mean of 28.3711.8 lymph
nodes per patient was dissected. As for the chemo or radiation
therapies after surgery, all patients received oral administration
of 5-fluorouracil (5-FU; 200mgbody
 1day
 1) for more than 2
months after the operation. None of the patients received
radiotherapy after surgery. After operation, routine follow-up
consisted of a physical examination, blood examination (including
carcinoembryonic antigen, CA19-9 levels), radiological examina-
tion, endoscopic examination, computed tomography and ultra-
sonography. Follow-up examinations were performed every 3
months for the first postoperative year and then at intervals of
between 6 and 12 months for at least 5 years. Of the 213 patients in
our series, 116 patients were still alive with no recurrences at the
time of the last follow-up (control group) and 97 had died from
recurrent gastric carcinoma. The recurrence sites in the 97 patients
were precisely determined by radiological examination, endo-
scopic examination, computed tomography, ultrasonography or
scintigraphy, and the recurrence pattern was divided into three
groups: peritoneal, haematogenous and locoregional recurrences.
Peritoneal recurrence occurred in 60 patients, haematogenous
recurrence occurred in 32 patients and locoregional recurrence
occurred in 18 patients (Figure 1). Haematogenous recurrence
occurred in the liver in 29 patients, in the lung in five patients and
in the brain in three patients. Locoregional recurrence occurred in
the lymph node, in 16 patients and in the anastomosis or stump in
two patients.
Clinicopathologic review
Serial 5-mm-thick tissue sections of the entire tumour were
prepared from the resected specimens fixed with 10% buffered
formalin, embedded in paraffin and stained with haematoxylin and
eosin (H&E). Clinicopathologic findings such as age, gender,
tumour size, tumour location, depth of invasion, growth pattern,
lymphatic invasion, blood vessel invasion and lymph node
metastasis were reviewed according to the Japanese Classification
of Gastric Carcinoma (Japanese Gastric Cancer Association, 1998).
In the present study, the tumours were classified histologically as
either differentiated or undifferentiated, according to the criteria
described by Nakamura et al (1968).
Immunohistochemical staining
The following mouse monoclonal antibodies were used: 45M1
(Novocastra Laboratories Ltd, UK), diluted 1:50, to detect HGM;
CLH5 (Novocastra Laboratories Ltd), diluted 1:50, to detect MUC6
glycoprotein; Ccp58 (Novocastra Laboratories Ltd), diluted 1:100,
to detect MUC2 glycoprotein; and 56C6 (Novocastra Laboratories
Ltd), diluted 1:40, to detect CD10 glycoprotein expression. 45M1
and CLH5 were examined as G-phenotype markers, and Ccp58 and
56C6 were examined as I-phenotype markers. 45M1 recognises the
mucin epitope located in the peptide core of HGM, which is
synonymous with MUC5AC. This antibody is known to react with
surface foveolar cells in the stomach (Bara et al, 1998; Nollet et al,
2002). MUC6 glycoprotein is expressed in mucous cells of the neck
zone of oxyntic mucosa and in antral glands (De Bolos et al, 1995;
Reis et al, 1999; Machado et al, 2000). MUC2 glycoprotein, also
known as the ‘intestinal-mucin-related protein antigen’, is an
intestinal apomucin and is known to be also expressed in the
supranuclear area of the goblet cells in regions showing intestinal
metaplasia in the stomach (Kim and Gum, 1995; Sakamoto et al,
1997; Baldus et al, 1998; Utsunomiya et al, 1998; Reis et al, 1999;
Machado et al, 2000). CD10 glycoprotein is a 100-kDa cell
metalloendopeptidase that inactivates a variety of biologically
active peptides and is known to be expressed on the brush border
of intestinal epithelial cells as well as in the germinal centres of
lymphoid follicles and the microvilli of the kidney (Ronco et al,
1984; Trejdosiewicz et al, 1985).The avidin–biotinyl-peroxidase
complex immunohistochemical method was used for all immuno-
Peritoneal
51 (52.6%)
4 (4.1%)
24 (24.7%)
0 (0%)
4 (4.1%) 5 (5.2%)
9 (9.3%)
Locoregional
Haematogenous
Figure 1 Recurrence patterns in 97 patients after curative resection.
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(Hsu et al, 1981).
With regard to the evaluations of HGM, MUC6, MUC2 and CD10
staining, distinct staining in more than 5% of the tumour cells was
recorded as positive immunoreactivity for the relevant marker.
These immunohistochemical methods were used to classify the
tumours into four different phenotypes: tumours with G-
phenotypic cells accounting for more than 5% of their cell
population were classified as G- phenotype carcinomas (Figure 2);
those with I-phenotypic cells accounting for more than 5% of their
cell population were classified as I-phenotype carcinomas
(Figure 3); those with both gastric and intestinal phenotypic cells
accounting for more than 5% of their cell population were
classified as GI-phenotype carcinomas; and those with both
gastric and intestinal phenotypic cells accounting for less than
5% of their cell population were regarded as carcinomas of
Figure 2 (A–C) Gastric carcinoma of the G-phenotype. (A)
Histological features (H&E, original magnification  400). (B) Human
gastric mucin is expressed in the cancer cell cytoplasm (45M1, original
magnification  400). (C) MUC6 glycoprotein is also expressed in the
cancer cell cytoplasm (CLH5, original magnification  400).
Figure 3 (A–C) Gastric carcinoma of the I-phenotype. Histological
features (H&E, original magnification  200). (B) MUC2 glycoprotein is
expressed in the cancer cell cytoplasm (Ccp58, original magnification
 200). (C) CD10 glycoprotein is also expressed on the luminal surfaces
of cancerous glands (56C6, original magnification  200).
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Yao et al, 2002).
The histopathological and immunohistochemical examinations
were independently performed by two observers (Tajima and
Yamazaki). The results were then compared, and any discrepancies
were resolved by consensus after further histopathological review.
Statistical analysis
Statistical calculations were performed using the Stat View
software package (version 5.0; Abacus Concepts, Inc., Berkeley,
CA, USA). The data were analysed using Student’ t-test or Mann–
Whitney U-test, in addition to the w
2 test or Fisher’ exact test.
Differences of Po0.05 were considered significant.
RESULTS
Relations between recurrence patterns and
clinicopathological features
The relations between the recurrence patterns and the clinico-
pathological features are shown in Table 1. Peritoneal recurrence
was significantly associated with a larger tumour size (Po0.0001),
a deeper depth of invasion (Po0.0001) and higher incidences of
tumours with whole tumour location (P¼0.012), undifferentiated-
type tumours (P¼0.0036), infiltrative growth tumours
(P¼0.0009) and lymph node metastasis (P¼0.0002), compared
with the control group. Haematogenous recurrence was signifi-
cantly associated with a higher mean age (P¼0.016), a higher
male-to-female ratio (P¼0.02) and higher incidences of blood
vessel invasion (P¼0.032) and lymph node metastasis
(P¼0.0061), compared with the control group. No significant
differences in the evaluated clinicopathological factors were
observed between patients with locoregional recurrence and the
control group.
Relations between recurrence patterns and expressions
of HGM, MUC6, MUC2 and CD10
The relations between the recurrence patterns and the expressions
of HGM, MUC6, MUC2 and CD10 are shown in Table 2. The
expressions of HGM, MUC6, MUC2 and CD10 were observed in
73.3, 61.7, 30.0 and 15.0% of patients in the peritoneum recurrence
group, respectively; in 43.8, 43.8, 37.5 and 43.8% of patients in the
haematogenous recurrence group, respectively; in 66.7, 66.7, 50.0
and 16.7% of patients in the locoregional recurrence group,
respectively; and in 54.3, 62.9, 61.2 and 23.3% of patients in the
control group, respectively. Peritoneal recurrence was significantly
associated with HGM-positive tumours (P¼0.022) and MUC2-
negative tumours (P¼0.0002), compared with the control group.
Haematogenous recurrence was significantly associated with
MUC2-negative tumours (P¼0.028) and CD10-positive tumours
(P¼0.039), compared with the control group. No significant
differences in expression were observed between the locoregional
recurrence group and the control group.
Relations between recurrence patterns and the phenotypic
marker expression patterns of the tumours
The relations between the recurrence patterns and the phenotypic
marker expression patterns of the tumours are shown in Table 3.
G-, GI-, I- and UC-phenotype tumours composed 58.3, 26.7, 8.3
and 6.7% of the peritoneum recurrence group, respectively; 25.0,
37.5, 25.0 and 12.5% of the haematogenous recurrence group,
respectively; 44.4, 44.4, 11.1 and 0% of the locoregional recurrence
group, respectively; and 28.4, 51.7, 15.5 and 4.3% of the control
group, respectively. Peritoneal recurrence was significantly asso-
ciated with G-phenotype tumours, compared with the control
group (P¼0.0002). No significant differences in the phenotypic
marker expression patterns of tumours in the haematogenous or
locoregional recurrence groups were found, when compared with
the control group.
DISCUSSION
Several studies on the relationship between recurrence patterns of
gastric carcinoma after surgery and clinicopathological character-
istics have been performed (Maehara et al, 1996; Yoo et al, 2000;
Ohno et al, 2003; Roviello et al, 2003). Reported risk factors for
peritoneal recurrence include an undifferentiated histologic type,
infiltrative tumour growth and serosal invasion (Maehara et al,
Table 1 Relations between recurrence patterns and clinicopathological
characteristics
Peritoneal
(n¼60)
Haematogenous
(n¼32)
Locoregional
(n¼18)
Control
(n¼116)
Age (years)
a 64.1714.5 67.9714.0 69.0712.3 63.1711.6
Gender
b
Male 33 (55.0%) 27 (84.4%) 16 (88.9%) 71 (61.2%)
Female 27 (45.0%) 5 (15.6%) 2 (11.1%) 45 (38.8%)
Tumour size
c
60mmX 15 (25.0%) 15 (46.9%) 7 (38.9%) 69 (59.5%)
60mmo 45 (75.0%) 17 (53.1%) 11 (61.1%) 47 (40.5%)
Tumour location
d
Upper 15 (25.0%) 12 (37.5%) 5 (27.8%) 34 (29.3%)
Middle 16 (26.7%) 6 (18.8%) 5 (27.8%) 39 (33.6%)
Lower 19 (31.7%) 10 (31.3%) 7 (38.9%) 40 (34.5%)
Whole 10 (16.7%) 4 (12.5%) 1 (5.6%) 3 (2.6%)
Histologic type
e
Differentiated 17 (28.3%) 16 (50.0%) 8 (44.4%) 61 (52.6%)
Undifferentiated 43 (71.7%) 16 (50.0%) 10 (55.6%) 55 (47.4%)
Depth of invasion
f
mp. ss 8 (13.3%) 15 (46.9%) 6 (333%) 63 (54.3%)
se, si 52 (86.7%) 17 (53.1%) 12 (66.7%) 53 (45.7%)
Growth pattern
g
Expansive 18 (30.0%) 18 (56.3%) 8 (44.4%) 67 (57.8%)
Infiltrative 42 (70.0%) 14 (43.8%) 10 (55.6%) 49 (42.2%)
Lymphatic invasion
Negative 7 (11.7%) 4 (12.5%) 2 (11.1%) 24 (20.7%)
Positive 53 (88.3%) 28 (87.5%) 16 (88.9%) 92 (79.3%)
Blood vessel
invasion
h
Negative 37 (61.7%) 11 (34.4%) 6 (33.3%) 67 (57.8%)
Positive 23 (38.3%) 21 (65.6%) 12 (66.7%) 49 (42.2%)
Lymph node
metastasis
i
Negative 7 (11.7%) 4 (12.5%) 4 (22.2%) 47 (40.5%)
Positive 53 (883%) 28 (87.5%) 14 (77.8%) 69 (59.5%)
mp¼muscularic propria; ss¼subserasa; se¼serosa exposed; si¼serosa-infiltrating
adjacent tissue.
aP¼0.016 (haematogenous vs control).
bP¼0.0057 (peritoneal vs
haematogenous) and P¼0.02 (haematogenous vs control).
cPo0.001 (peritoneal vs
control).
dP¼0.012 (peritoneal vs control).
eP¼0.0036 (peritoneal vs control).
fP¼0.001 (peritoneal vs haematogenous) and Po0.0001 (peritoneal vs control).
gP¼0.026 (peritoneal vs haematogenous) and P¼0.0009 (peritoneal vs control).
hP¼0.023 (peritoneal vs haematogenous) and P¼0.032 (haematogenous vs
control).
iP¼0.0002 (peritoneal vs control) and P¼0.0061 (haematogenous vs
control).
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haematogenous recurrence, on the other hand, include blood
vessel invasion, a differentiated histologic type and expansive
tumour growth (Maehara et al, 1996; Yoo et al, 2000; Ohno et al,
2003). In the present study, peritoneal recurrence was significantly
associated with a larger tumour size, a deeper depth of invasion,
and higher incidences of tumours with whole tumour location,
undifferentiated-type tumours, infiltrative growth tumours and
lymph node metastasis, compared with the control group, while
haematogenous recurrence was significantly associated with a
higher mean age, a higher male-to-female ratio, and higher
incidences of blood vessel invasion and lymph node metastasis.
Therefore, clinicopathological analysis appears to be a useful
approach predicting recurrence patterns after surgery. Further-
more, our present results clearly show that recurrence patterns
after curative resection vary with the gastric and intestinal
phenotypic marker expression of the tumour. To the best of our
knowledge, this is the first report describing an association
between phenotypic marker expression in gastric carcinomas and
the recurrence pattern after surgery.
Our present results revealed that the incidences of HGM-
positive tumours and MUC2-negative tumours were significantly
higher in the peritoneal recurrence group than in the control
group. Taking into account the expression combinations of HGM,
MUC6, MUC2 and CD10, the incidence of G-phenotype tumours
was significantly higher in the peritoneal recurrence group than in
the control group. With respect to the relations between the
clinicopathological findings and HGM expression, we previously
reported that HGM expression was correlated with a higher
proportion of infiltrative tumours and undifferentiated-type
tumours in advanced gastric carcinomas; we also found a higher
incidence rate of infiltrative tumours in G-phenotype tumours
than in I-phenotype tumours (Tajima et al, 2001b). Even
differentiated gastric carcinomas with a G-phenotype have been
reported to be more likely to transform into undifferentiated
carcinomas and exhibit infiltrative growth to deeper layers of the
invaded surrounding structures through the loss of E-cadherin
function, compared with differentiated gastric carcinomas with an
I-phenotype (Endoh et al, 1999; Saito et al, 2001; Tajima et al,
2001b). Undifferentiated carcinomas with infiltrative growth have
been reported to be mainly noted in cases with an advanced level
of invasion into the serosal layer or adjacent organs (Maehara et al,
1996). As described above, our present results showed that
peritoneal recurrence was dominant among undifferentiated
tumours and tumours exhibiting serosal invasion, infiltrative
tumour growth and lymph node metastasis; these clinicopatholo-
gical characteristics have also been correlated with G-phenotype
and HGM-positive tumours (Tajima et al, 2001b). In these cases,
the cancerous cells are thought to infiltrate the gastric wall,
penetrate the serosa and disseminate trans-serosally to the
peritoneum. Therefore, the association between G-phenotype or
HGM-positive tumours and peritoneal recurrence in the present
study may be attributed to the clinicopathological characteristics
of the G-phenotype or HGM-positive tumours.
Haematogenous metastasis is thought to mainly occur when
cancerous cells released from the primary site enter the blood
vessel system and are transported to a target organ, where
attachment and proliferation occurs (Maehara et al, 1996). Thus,
blood vessel invasion is considered to be one of the most
important factors for haematogenous metastasis. In the present
study, the incidences of MUC2-negative tumours and CD10-
positive tumours were significantly higher in the haematogenous
recurrence group than in the control group. Concerning the
relations between the clinicopathological findings and MUC2
expression, Utsunomiya et al (1998) reported that MUC2
expression in tumours was correlated with lower levels of invasion
and lymph node metastasis in gastric carcinomas. In the present
study, peritoneal recurrence was also strongly associated with
MUC2-negative tumours. Among colorectal carcinomas, MUC2-
positive tumours have been reported to have a relatively good
prognosis, with a low incidence of liver metastasis (Hanski et al,
1997). Therefore, MUC2 expression might be inversely correlated
with tumour aggressiveness in gastric carcinomas. As for the
relations between the clinicopathological findings and CD10
expression, we previously reported that CD10 expression was
correlated with a higher male-to-female ratio of patients, a
differentiated histologic type, expansive tumour growth and blood
vessel invasion in advanced gastric carcinomas (Tajima et al,
2001b); these clinicopathological characteristics have also been
associated with haematogenous metastasis (Maehara et al, 1996;
Yoo et al, 2000; Roviello et al, 2003). We also reported a higher
Table 2 Relations between recurrence patterns and expressions of
human gastric mucin, MUC6, MUC2 and CDIO
Peritoneal
(n¼60)
Haematogenous
(n¼32)
Locoregional
(n¼18)
Control
(n¼116)
Human gastric
mucin
a
Negative 16 (26.7%) 18 (56.3%) 6 (33.3%) 53 (45.7%)
Positive 44 (73.3%) 14 (43.8%) 12 (66.7%) 63 (54.3%)
MUC6
Negative 23 (38.3%) 18 (56.3%) 6 (33.3%) 43 (37.1%)
Positive 37 (61.7%) 14 (43.8%) 12 (66.7%) 73 (62.9%)
MUC2
b
Negative 42 (70.0%) 20 (62.5%) 9 (50.0%) 45 (38.8%)
Positive 18 (30.0%) 12 (37.5%) 9 (50.0%) 71 (61.2%)
CD10
c
Negative 51 (85.0%) 18 (56.3%) 15 (83.3%) 89 (76.7%)
Positive 9 (15.0%) 14 (43.8%) 3 (16.7%) 27 (23.3%)
aP¼0.01 (peritoneal vs haematogenous) and P¼0.022 (peritoneal vs control).
bP¼0.0002 (peritoneal vs control) and P¼0.028 (haematogenous vs control).
cP¼0.0054 (peritoneal vs haematogenous) and P¼0.039 (haematogenous vs
control).
Table 3 Relations between recurrence patterns and the phenotypic marker expression pattern of the tumour
Peritoneal
(n¼60)
Haematogenous
(n¼32)
Locoregional
(n¼18)
Control
(n¼116)
Gastric phenotype
a 35 (58.3%) 8 (25.0%) 8 (44.4%) 33 (28.4%)
Gastric and intestinal mixed phenotype
b 16 (26.7%) 12 (37.5%) 8 (44.4%) 60 (51.7%)
Intestinal phenotype 5 (8.3%) 8 (25.0%) 2 (11.1%) 18 (15.5%)
Unclassified phenotype 4 (6.7%) 4 (12.5%) 0 (0%) 5 (4.3%)
aP¼0.0046 (peritoneal vs haematogenous) and P¼0.0002 (peritoneal vs control).
bP¼0.0025 (peritoneal vs control).
Phenotypic marker expression in gastric carcinoma
Y Tajima et al
1346
British Journal of Cancer (2004) 91(7), 1342–1348 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yincidence rate of synchronous liver metastasis in CD10-positive
tumours than in CD10-negative tumours (Tajima et al, 2001b).
Among colorectal carcinomas, CD10-positive tumours exhibited a
higher incidence of blood vessel invasion and were at increased
risk of liver metastais (Yao et al, 2002). Moreover, an ultra-
structural study by Shimizu et al (2000) revealed that microvilli, as
demonstrated by CD10 expression, were generated on the luminal
surface of metastatic liver adenocarcinomas. Based on these
previous data and the present findings, CD10-positive gastric
carcinomas appear to have a strong tendency toward blood vessel
invasion, leading to haematogenous metastasis.
In the present study, we demonstrated that the recurrence
patterns after curative resection, such as peritoneal and haema-
togenous recurrences, vary with the phenotypic marker expression
of the tumour. Therefore, evaluating the gastric and intestinal
phenotypic marker expression of tumours may be useful for
predicting the recurrence patterns of the gastric carcinomas after
surgery. Careful postoperative follow-up is vital for patients with a
high-risk peritoneal or haematogenous recurrence, since the
prognosis of patients with recurrence is very poor; additional
and intensive therapies after surgery may be indicated for such
cases. The results of several randomised trials have demonstrated
that intraperitoneal chemotherapy in normothermic or hyperther-
mic patients tends to improve survival rates and decrease the
incidence of peritoneal failure compared with surgery alone (Yu
et al, 1998; Fujimoto et al, 1999). For patients with a high risk of
peritoneal recurrence, intraperitoneal chemotherapy may thus
be a valuable adjuvant at operation or early in the postoperative
period.
Obvious differences in the biological behaviour of tumours with
different phenotypic marker expressions have been reported.
Kabashima et al (2002) reported that G-phenotype tumours could
potentially degrade the extracellular matrix through the over-
expression of matrix metalloproteinases, compared with I-
phenotype tumours. Shibata et al (2003) reported that the
apoptotic index/proliferative index ratio was significantly lower
in G-phenotype tumours than in I-phenotype tumours. We
previously reported that patients with G-phenotype tumours
have a poorer prognosis than those with I-phenotype tumours
among patients with advanced gastric carcinoma (Tajima et al,
2001b). We also previously reported that postoperative chemother-
apy with 5-FU was effective for patients with G-phenotype
tumours, since the incidence of intratumoral expression of
thymidylate synthase, the target enzyme of 5-FU, was significantly
low in G-phenotype tumours (Tajima et al, 2003). These previous
data and our present findings suggest that appropriate post-
operative follow-up programmes and therapeutic approaches may
differ according to the phenotypic marker expression of the
tumour.
In conclusion, our present findings show that the gastric and
intestinal phenotypic marker expression of the tumour, deter-
mined by the HGM, MUC6, MUC2 and CD10 expression patterns,
may be used to predict the recurrence pattern of gastric
carcinomas after curative resections.
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